None Yulistiani, Indira Dhany Kharismawati, I Dewa Gede Ugrasena, Mariyatul Qibtiyah
{"title":"别嘌呤醇给药对肿瘤溶解综合征(TLS)和高危TLS患儿尿酸水平和肾功能的影响","authors":"None Yulistiani, Indira Dhany Kharismawati, I Dewa Gede Ugrasena, Mariyatul Qibtiyah","doi":"10.46542/pe.2023.234.8791","DOIUrl":null,"url":null,"abstract":"Background: Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency because of the release of tumour cell components such as uric acid, which can lead to hyperuricemia and acute kidney injury (AKI). Objective: To analyse serum uric acid, creatinine, and BUN levels pre- and post-allopurinol administration. Method: This study was a prospective observational study conducted from March to July 2020. Inclusion criteria were haematological malignancies in paediatric patients with TLS and high-risk TLS who received allopurinol 10 mg/kg/day in 2-3 divided doses. Collected data were the serum uric acid, creatinine, and BUN levels pre- and post-allopurinol administration. Result: There were 14 sample in total during the study. There was a significant difference in uric acid level on day six after allopurinol administration compared to baseline in patients with high-risk TLS (p < 0.05). Conclusion: Allopurinol was inadequate in reducing uric acid levels in TLS patients but adequate in reducing uric acid levels in patients with high-risk TLS.","PeriodicalId":19944,"journal":{"name":"Pharmacy Education","volume":"70 1","pages":"0"},"PeriodicalIF":0.5000,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Allopurinol administration on the uric acid level and kidney function in paediatrics with tumour lysis syndrome (TLS) and high-risk TLS\",\"authors\":\"None Yulistiani, Indira Dhany Kharismawati, I Dewa Gede Ugrasena, Mariyatul Qibtiyah\",\"doi\":\"10.46542/pe.2023.234.8791\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency because of the release of tumour cell components such as uric acid, which can lead to hyperuricemia and acute kidney injury (AKI). Objective: To analyse serum uric acid, creatinine, and BUN levels pre- and post-allopurinol administration. Method: This study was a prospective observational study conducted from March to July 2020. Inclusion criteria were haematological malignancies in paediatric patients with TLS and high-risk TLS who received allopurinol 10 mg/kg/day in 2-3 divided doses. Collected data were the serum uric acid, creatinine, and BUN levels pre- and post-allopurinol administration. Result: There were 14 sample in total during the study. There was a significant difference in uric acid level on day six after allopurinol administration compared to baseline in patients with high-risk TLS (p < 0.05). Conclusion: Allopurinol was inadequate in reducing uric acid levels in TLS patients but adequate in reducing uric acid levels in patients with high-risk TLS.\",\"PeriodicalId\":19944,\"journal\":{\"name\":\"Pharmacy Education\",\"volume\":\"70 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2023-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacy Education\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.46542/pe.2023.234.8791\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"EDUCATION, SCIENTIFIC DISCIPLINES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy Education","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46542/pe.2023.234.8791","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"EDUCATION, SCIENTIFIC DISCIPLINES","Score":null,"Total":0}
Effect of Allopurinol administration on the uric acid level and kidney function in paediatrics with tumour lysis syndrome (TLS) and high-risk TLS
Background: Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency because of the release of tumour cell components such as uric acid, which can lead to hyperuricemia and acute kidney injury (AKI). Objective: To analyse serum uric acid, creatinine, and BUN levels pre- and post-allopurinol administration. Method: This study was a prospective observational study conducted from March to July 2020. Inclusion criteria were haematological malignancies in paediatric patients with TLS and high-risk TLS who received allopurinol 10 mg/kg/day in 2-3 divided doses. Collected data were the serum uric acid, creatinine, and BUN levels pre- and post-allopurinol administration. Result: There were 14 sample in total during the study. There was a significant difference in uric acid level on day six after allopurinol administration compared to baseline in patients with high-risk TLS (p < 0.05). Conclusion: Allopurinol was inadequate in reducing uric acid levels in TLS patients but adequate in reducing uric acid levels in patients with high-risk TLS.
期刊介绍:
Pharmacy Education journal provides a research, development and evaluation forum for communication between academic teachers, researchers and practitioners in professional and pharmacy education, with an emphasis on new and established teaching and learning methods, new curriculum and syllabus directions, educational outcomes, guidance on structuring courses and assessing achievement, and workforce development. It is a peer-reviewed online open access platform for the dissemination of new ideas in professional pharmacy education and workforce development. Pharmacy Education supports Open Access (OA): free, unrestricted online access to research outputs. Readers are able to access the Journal and individual published articles for free - there are no subscription fees or ''pay per view'' charges. Authors wishing to publish their work in Pharmacy Education do so without incurring any financial costs.